Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
31. |
ECCT/20/06/09 | HIV-CORE 006 A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa |
Principal Investigator(s) 1. Professor Walter Jaoko, Jaoko, Site(s) in Kenya 1. KAVI-Institute of Clinical Research (Nairobi City county) 2. KEMRI/ Wellcome Trust Research Programme (Kilifi county) |
09-09-2020 |
View |
32. |
ECCT/20/07/02 | RV 460 HIV Vaccine Trial A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine in Healthy HIV Uninfected Adults in Kenya |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI/US MRDA-A/K, KERICHO |
19-10-2020 |
View |
33. |
ECCT/20/10/01 | HIV-CORE 006 A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa. |
Principal Investigator(s) 1. Eduard J Sanders Site(s) in Kenya 1. KEMRI Mtwapa Research Clinic (Kilifi county) 2. KAVI-ICR Nairobi (Nairobi City county) |
19-11-2020 |
View |
34. |
ECCT/20/06/01 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults |
Principal Investigator(s) 1. Prof Walter Jaoko Godfrey Jaoko Site(s) in Kenya 1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county) |
02-12-2020 |
View |
35. |
ECCT/20/11/02 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (IAVI C100) |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya 1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county) 2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county) |
03-03-2021 |
View |
36. |
ECCT/21/03/05 | Unithiol Phase I TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming Phase 1 (Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Kenyan Adults) |
Principal Investigator(s) 1. Michael Abouyannis 2. Mainga Patience Mayeso Hamaluba Site(s) in Kenya KEMRI Wellcome Trust Research Programme |
07-08-2021 |
View |
37. |
ECCT/20/06/05 | SEVUSMART Trial SEVUSMART TRIAL Sevuparin as a potential adjunctive therapy in children with severe malaria |
Principal Investigator(s) 1. Kathryn Maitland Maitland Site(s) in Kenya Kilifi County Hospital |
08-08-2021 |
View |
38. |
ECCT/22/03/03 | HVTN 140/HPTN 101 A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants_HVTN 140/HPTN 101 |
Principal Investigator(s) 1. Josphat kosgei Site(s) in Kenya KEMRI WRP, KERICHO |
12-05-2022 |
View |
39. |
ECCT/22/03/01 | The \"NOVATION-1\" Trial A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 |
Principal Investigator(s) 1. Dr John Kinuthia Site(s) in Kenya 1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. KEMRI Kericho (Kericho county) 4. KEMRI Siaya (Kisumu county) 5. Kenyatta National Hospital (Nairobi City county) |
27-05-2022 |
View |
40. |
ECCT/22/04/02 | GO42144 A PHASE Ia/Ib DOSE-ESCALATION AND DOSE- EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITYOF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS |
Principal Investigator(s) 1. Mansoor Noorali Saleh Site(s) in Kenya Aga Khan University, Nairobi |
19-08-2022 |
View |